ARBUTUS BIOPHARMA CORP
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$4.21
-1.64%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
-7.7%
3 months
-3.4%
6 months
-2.5%
1 year
-13.0%
Year to date
-12.5%
52-week range
$3.67 – $5.22
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$832.9M
P/E
5.4
P/B
3.2
P/S
4.6
Revenue
$181.72M
Net income
$153.05M
Diluted EPS
0.79
Gross margin
100.00%
Net margin
84.20%
Return on equity
91.00%
Total debt
$3.63M
Cash
$19.17M
Free cash flow
-$24.27M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $1.01M | -$5.14M | 100.00% | -507.20% | -$6.02M |
| Mar 31, 2026 | $179.13M | $169.7M | 100.00% | 94.70% | -$8.11M |
| Dec 31, 2025 | $1.05M | -$3.76M | 100.00% | -357.40% | -$4.33M |
| Sep 30, 2025 | $529K | -$7.74M | 100.00% | -1463.50% | -$5.82M |
| Jun 30, 2025 | $10.74M | $2.52M | 100.00% | 23.50% | -$15.74M |
| Mar 31, 2025 | $1.76M | -$24.53M | 100.00% | -1390.40% | -$13.39M |
| Dec 31, 2024 | $1.57M | -$12.53M | 100.00% | -796.20% | -$10.4M |
| Sep 30, 2024 | $1.34M | -$19.72M | 100.00% | -1472.50% | -$20.74M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent ABUS news
All market newsNo ticker-linked stories are in the current archive.